Parexel and Veeva Systems collaborate to advance clinical trial technology
Parexel and Veeva Systems are set to accelerate clinical trials through technology and process innovation, as part of a strategic collaboration.
Latest News
View More
ObvioHealth Q&A: connecting DCT dots with remote tech
The move towards decentralised clinical trials has been accelerated by Covid-19, and the tech that underpins remote trials is evolving…
Latest News
View More
Qlaris Bio commences enrolment in glaucoma therapy trial
Qlaris Bio has announced the enrolment of the first patient in the Phase I/II clinical programme of its lead investigational product candidate, QLS-101, for treating…
Ideaya doses first patient in solid tumour treatment trial
Ideaya Biosciences has announced first-patient-in (FPI) in Phase I clinical trial of methionine adenosyltransferase 2a (MAT2A) inhibitor IDE397 for treating methylthioadenosine phosphorylase (MTAP) deletion solid…
Parexel and Veeva Systems collaborate to advance clinical trial technology
Parexel and Veeva Systems are set to accelerate clinical trials through technology and process innovation, as part of a strategic…
Quantum Leap concludes icatibant portion of I-SPY COVID Trial
Quantum Leap Healthcare Collaborative (QLHC) has concluded the enrolment in the icatibant arm of the I-SPY COVID Trial testing various…
ERT’s Business Intelligence suite expands to include clinical trial reporting
US-based global data and technology company eResearch Technology (ERT) has announced the expansion of its Business Intelligence suite to include…
Romark’s investigational Covid-19 drug lowers disease progression in trial
Romark has reported that initial results from a Phase III clinical trial of its investigational new drug candidate NT-300 (nitazoxanide…
Expert Commentary & Analysis
View MoreTakeda’s Phase III mobocertinib study in first-line NSCLC on enrolment pause for futility analysis; decision on next steps possible in three months, investigators say
Takeda Pharmaceuticals’ Phase III TAK-788 (mobocertinib) study in first-line (1L) EGFR exon 20 mutation non-small cell lung cancer (NSCLC) is on recruitment hold due to an ongoing futility analysis, two investigators…
AstraZeneca/Oxford unblinded South Africa Phase I/II last week to administer Covid-19 vaccine to placebo volunteers, third dose in experimental arm, source says
AstraZeneca and the University of Oxford’s South Africa-based Phase I/II trial investigating its Covid-19 vaccine, Vaxzevria (AZD1222), started unblinding participants last week, a source familiar with the trial said. Participants…
LoA Update: Ionis’ donidalorsen sodium for HAE sees an 8-point spike in FDA regulatory potential following positive Phase II
As of 31 March, the likelihood of approval (LoA) for Ionis Pharmaceuticals’ IONIS-PKK-LRx (donidalorsen sodium) for hereditary angioedema (HAE) rose 8 points in the aftermath of positive topline Phase II results,…
Latest Themes
View More
THREAD Q&A: bridging the gap between patients and trials with social media
THREAD, a tech-focused service provider that enables decentralised clinical trials, has recently penned a partnership with CureClick, a community-powered platform that harnesses social media influencers...
Akili presents more positive trial data for ADHD gaming therapy
Akili Interactive has published data from its STARS-Adjunct trial supporting the efficacy of EndeavorRx, its attention-deficit hyperactivity disorder (ADHD) video game therapy for kids, in...
MHRA pilot aims to boost patient involvement in clinical research
In a bid to put patient involvement at the heart of drug development and clinical trials, the Medicines and Healthcare products Regulatory Agency (MHRA) has...
Company Whitepapers
View MoreCompany A-Z
View More
VaLea Clinical Trials
Patient-Centric Services for In-Home or Alternate-Site Clinical Trials Settings
LoA Update: Chengdu Kanghong Pharmaceuticals’ Phase III ophthalmic agent drops 7 points in AMD after trial stop
The likelihood of approval (LoA) of Chengdu Kanghong Pharmaceuticals’ (SHE:002773) Phase III conbercept in neovascular age-related macular degeneration (AMD) dropped 7 points as of 12 April, according to GlobalData’s LoA…